ProCE Banner Activity

Identifying and Managing Immune-Related Adverse Events in Patients With Advanced Gastroesophageal Cancers Receiving Checkpoint Inhibitors

Clinical Thought
With widening use of immune checkpoint inhibitors in patients with gastroesophageal cancer, it is critical for clinicians to stay abreast of the unique adverse events associated with these agents

Released: March 22, 2019

Expiration: March 20, 2020

No longer available for credit.

Share

Faculty

Axel Grothey

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Axel Grothey, MD, has disclosed that he has received financial or material support from Bayer and Roche/Genentech.